BAVENCIO (Merck Healthcare Pty Ltd)
Product name
BAVENCIO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
190 working days (255)
Active ingredients
avelumab
Registration type
EOI
Indication
BAVENCIO (concentrated solution for injection) in combination with axitinib is now also indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC).